{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:25:00Z","timestamp":1787678700101,"version":"build-2784847793"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"DOI":"10.1007\/s10620-026-10176-5","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:36:55Z","timestamp":1787632615000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Holding the Line: Navigating Upadacitinib-Induced Neutropenia in Refractory Ulcerative Colitis"],"prefix":"10.1007","author":[{"given":"Rohan","family":"Moghe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tenzin","family":"Choden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"10176_CR1","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113\u20132128. https:\/\/doi.org\/10.1016\/S0140-6736(22)00581-5.","journal-title":"Lancet."},{"key":"10176_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13688","volume":"17","author":"MEF Mohamed","year":"2024","unstructured":"Mohamed MEF, Bhatnagar S, Parmentier JM, Nakasato P, Wung P. Upadacitinib: mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17:e13688. https:\/\/doi.org\/10.1111\/cts.13688.","journal-title":"Clin Transl Sci."},{"key":"10176_CR3","doi-asserted-by":"publisher","first-page":"i1330","DOI":"10.1093\/ecco-jcc\/jjae190.0854","volume":"19","author":"M Sharpe","year":"2025","unstructured":"Sharpe M, Khose S, Fletcher J, Samanta S. P0680 upadacitanib in inflammatory bowel disease: evaluating the risk of neutropenia and impact of thiopurine exposure. J Crohn\u2019s Colitis. 2025;19:i1330\u2013i1331. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae190.0854.","journal-title":"J Crohn\u2019s Colitis."},{"key":"10176_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1598972","author":"C Zhang","year":"2025","unstructured":"Zhang C, Zhiwen F, Jinmei Liu X, Chen YZ, Xie J. Safety profile and dose-dependent adverse events of upadacitinib in randomized clinical trials: a systematic review and meta-analysis. Front Pharmacol. 2025. https:\/\/doi.org\/10.3389\/fphar.2025.1598972.","journal-title":"Front Pharmacol."},{"key":"10176_CR5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s12664-024-01720-0","volume":"44","author":"BTQ Falcon","year":"2025","unstructured":"Falcon BTQ, de Mello Guimaraes T, Halpern GA, Gomes C, de Mello Guimaraes T. Insights into adverse events and safety profile of upadacitinib in the management of inflammatory bowel diseases\u2014a meta-analysis of randomized controlled trials. Indian J Gastroenterol. 2025;44:154\u2013162. https:\/\/doi.org\/10.1007\/s12664-024-01720-0.","journal-title":"Indian J Gastroenterol."},{"key":"10176_CR6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s40744-023-00624-3","volume":"11","author":"C Charles-Schoeman","year":"2024","unstructured":"Charles-Schoeman C, Giles JT, Lane NE et al. Impact of upadacitinib on laboratory parameters and related adverse events in patients with RA: integrated data up to 6.5 years. Rheumatol Ther. 2024;11:157\u2013175. https:\/\/doi.org\/10.1007\/s40744-023-00624-3.","journal-title":"Rheumatol Ther."},{"key":"10176_CR7","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1172\/JCI26674","volume":"115","author":"K Kaushansky","year":"2005","unstructured":"Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest 2005;115:3339\u20133347. https:\/\/doi.org\/10.1172\/JCI26674.","journal-title":"J Clin Invest"},{"key":"10176_CR8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40262-022-01191-6","volume":"62","author":"AV Ponce-Bobadilla","year":"2023","unstructured":"Ponce-Bobadilla AV, Stodtmann S, Eckert D, Zhou W, Liu W, Mohamed MEF. Upadacitinib population pharmacokinetics and exposure-response relationships in ulcerative colitis patients. Clin Pharmacokinet. 2023;62:101\u2013112. https:\/\/doi.org\/10.1007\/s40262-022-01191-6.","journal-title":"Clin Pharmacokinet."},{"key":"10176_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13733","volume":"17","author":"S Bhatnagar","year":"2024","unstructured":"Bhatnagar S, Eckert D, Stodtmann S et al. Population pharmacokinetics and exposure-response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis. Clin Transl Sci. 2024;17:e13733. https:\/\/doi.org\/10.1111\/cts.13733.","journal-title":"Clin Transl Sci."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-10176-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-10176-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-10176-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:01:44Z","timestamp":1787677304000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-10176-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":9,"alternative-id":["10176"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-10176-5","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"18 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}